Source: Physics World
Researchers have developed an electrocatalytic implant that metabolizes excess blood glucose directly, bypassing the pharmaceutical approach that dominates diabetes treatment. If validated in human trials, this shifts management from systemic drug delivery to localized electrochemical intervention—the model pacemakers use for cardiac rhythm. The stakes are significant for the 400+ million people with type 2 diabetes, though manufacturing, biocompatibility, and long-term electrode degradation remain unresolved engineering challenges before commercialization.